{"id":"tacrolimus-capsule","safety":{"commonSideEffects":[{"rate":"25-50","effect":"Nephrotoxicity/renal impairment"},{"rate":"30-50","effect":"Hypertension"},{"rate":"15-30","effect":"Hyperglycemia/new-onset diabetes"},{"rate":"10-25","effect":"Neurotoxicity (tremor, headache, paresthesia)"},{"rate":"20-40","effect":"Infections"},{"rate":"10-20","effect":"Hyperkalemia"},{"rate":"10-20","effect":"Gastrointestinal disturbances"}]},"_chembl":{"chemblId":"CHEMBL3989887","moleculeType":"Small molecule","molecularWeight":"822.05"},"_dailymed":{"setId":"550a5cd4-fbf2-4c09-b577-6bde8fcbdf6e","title":"ASTAGRAF XL (TACROLIMUS EXTENDED-RELEASE CAPSULES) CAPSULE, COATED, EXTENDED RELEASE [ASTELLAS PHARMA US, INC.]"},"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Tacrolimus binds to the immunophilin FKBP12, and this complex inhibits calcineurin, a serine/threonine phosphatase essential for dephosphorylating NFAT (nuclear factor of activated T cells). By preventing NFAT nuclear translocation, tacrolimus suppresses the transcription of interleukin-2 and other T-cell activation genes, resulting in potent immunosuppression. This mechanism makes it effective for preventing organ rejection and treating autoimmune conditions.","oneSentence":"Tacrolimus inhibits calcineurin phosphatase, blocking T-cell activation and proliferation by preventing transcription of IL-2 and other cytokine genes.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T00:10:45.245Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Organ transplant rejection prophylaxis (kidney, heart, liver, pancreas)"},{"name":"Atopic dermatitis"},{"name":"Autoimmune conditions (off-label use in various settings)"}]},"trialDetails":[{"nctId":"NCT07412470","phase":"PHASE2, PHASE3","title":"A Study to Investigate the Efficacy and Safety of Frexalimab Versus Tacrolimus in Adults Undergoing Kidney Transplantation","status":"RECRUITING","sponsor":"Sanofi","startDate":"2026-03-13","conditions":"Kidney Transplant Rejection","enrollment":526},{"nctId":"NCT06120140","phase":"PHASE2","title":"Enhanced Dermatological Care to Reduce Rash and Paronychia in Epidermal Growth Factor Receptor (EGRF)-Mutated Non-Small Cell Lung Cancer (NSCLC) Treated First-line With Amivantamab Plus Lazertinib","status":"RECRUITING","sponsor":"Janssen Research & Development, LLC","startDate":"2024-02-16","conditions":"Carcinoma, Non-Small-Cell Lung","enrollment":300},{"nctId":"NCT03970096","phase":"PHASE2","title":"Graft Versus Host Disease-Reduction Strategies for Donor Blood Stem Cell Transplant Patients With Acute Leukemia or Myelodysplastic Syndrome (MDS)","status":"RECRUITING","sponsor":"Fred Hutchinson Cancer Center","startDate":"2019-11-19","conditions":"Acute Leukemia, Acute Lymphoblastic Leukemia, Acute Myeloid Leukemia","enrollment":120},{"nctId":"NCT07204275","phase":"PHASE2, PHASE3","title":"A Study to Evaluate Efficacy, Safety, and Tolerability of Povetacicept in Participants With Primary Membranous Nephropathy (pMN)","status":"RECRUITING","sponsor":"Vertex Pharmaceuticals Incorporated","startDate":"2025-09-30","conditions":"Primary Membranous Nephropathy","enrollment":176},{"nctId":"NCT05707377","phase":"PHASE2, PHASE3","title":"A Study to Examine the Efficacy and Safety of Zanubrutinib Given to Adults With Primary Membranous Nephropathy","status":"ACTIVE_NOT_RECRUITING","sponsor":"BeOne Medicines","startDate":"2023-04-17","conditions":"Primary Membranous Nephropathy","enrollment":178},{"nctId":"NCT04302870","phase":"PHASE2, PHASE3","title":"Motor Neurone Disease - Systematic Multi-Arm Adaptive Randomised Trial","status":"RECRUITING","sponsor":"University of Edinburgh","startDate":"2020-02-27","conditions":"Motor Neuron Disease, Amyotrophic Lateral Sclerosis","enrollment":1150},{"nctId":"NCT05252754","phase":"PHASE3","title":"Rectal Indomethacin and Oral Tacrolimus Versus Combination to Prevent Post-ERCP Pancreatitis","status":"RECRUITING","sponsor":"Johns Hopkins University","startDate":"2023-01-18","conditions":"Post-ERCP Acute Pancreatitis","enrollment":4874},{"nctId":"NCT01294020","phase":"PHASE2","title":"Study to Compare the Pharmacokinetics of Tacrolimus in Stable Pediatric Allograft Recipients Converted From Prograf® to Advagraf®","status":"COMPLETED","sponsor":"Astellas Pharma Europe Ltd.","startDate":"2011-05-25","conditions":"Intestine Transplantation, Kidney Transplantation, Lung Transplantation","enrollment":81},{"nctId":"NCT03841097","phase":"PHASE4","title":"Pulse Wave Velocity, Tacrolimus Time in Therapeutic Range and CV in African American Kidney Transplants","status":"ACTIVE_NOT_RECRUITING","sponsor":"Roy D. Bloom, MD","startDate":"2019-11-11","conditions":"Kidney Transplant; Complications","enrollment":60},{"nctId":"NCT07049172","phase":"NA","title":"Rituximab and Targeted Nursing for Pediatric Nephrotic Syndrome","status":"COMPLETED","sponsor":"Wuhan Children's Hospital","startDate":"2021-01-01","conditions":"Nephrotic Syndrome in Children","enrollment":91},{"nctId":"NCT04496479","phase":"PHASE2","title":"Allogenic Hepatocyte Transplantation Into Periduodenal Lymph Nodes","status":"RECRUITING","sponsor":"LyGenesis, Inc.","startDate":"2022-03-11","conditions":"End Stage Liver Disease","enrollment":12},{"nctId":"NCT06900777","phase":"NA","title":"Oral Tacrolimus vs Dexamethasone Micro-pulse Therapy in Pediatric Rapidly Progressing Vitiligo: A Multicenter RCT","status":"RECRUITING","sponsor":"Xijing Hospital","startDate":"2025-04-01","conditions":"Vitiligo, Child, Progressive Disease","enrollment":90},{"nctId":"NCT07003438","phase":"EARLY_PHASE1","title":"Study on the Efficacy and Safety of Fecal Microbiota Transplantation in the Treatment of Steroid - Dependent /Steroid-resistant Nephrotic Syndrome in Children","status":"NOT_YET_RECRUITING","sponsor":"Zhang Ting","startDate":"2025-06-01","conditions":"Steroid-Resistant Nephrotic Syndrome, Steroid-Dependent Nephrotic Syndrome","enrollment":120},{"nctId":"NCT04720326","phase":"PHASE4","title":"Bioavailability and Practicability of Envarsus Versus Advagraf in Liver Transplant Recipients","status":"ACTIVE_NOT_RECRUITING","sponsor":"Edward Geissler","startDate":"2020-12-23","conditions":"Prophylaxis Against Liver Transplant Rejection","enrollment":268},{"nctId":"NCT03640026","phase":"PHASE4","title":"Glucose Disorders Induced by Tacrolimus on Pre Transplantation Endstage Renal Disease Patients","status":"RECRUITING","sponsor":"Centre Hospitalier Departemental Vendee","startDate":"2019-03-08","conditions":"Kidney Failure, Chronic","enrollment":30},{"nctId":"NCT04646356","phase":"PHASE2","title":"Tacrolimus Trial for Hereditary Hemorrhagic Telangiectasia (HHT)","status":"COMPLETED","sponsor":"Unity Health Toronto","startDate":"2020-10-20","conditions":"Hereditary Hemorrhagic Telangiectasia, Epistaxis Nosebleed","enrollment":10},{"nctId":"NCT00866684","phase":"PHASE4","title":"Prevention of Skin Cancer in High Risk Patients After Conversion to a Sirolimus-based Immunosuppressive Protocol","status":"TERMINATED","sponsor":"Charite University, Berlin, Germany","startDate":"2007-01-01","conditions":"Skin Cancer","enrollment":44},{"nctId":"NCT02723591","phase":"PHASE4","title":"To Compare the Effects of Immediate-release Tacrolimus and Astagraf XL on Donor-Specific Antibody (DSA) Formation and the Development of Immune Activation (IA) in de Novo Kidney Transplant Recipients","status":"COMPLETED","sponsor":"Astellas Pharma Global Development, Inc.","startDate":"2016-09-09","conditions":"Kidney Transplantation","enrollment":599},{"nctId":"NCT06183892","phase":"NA","title":"Prospective, Multicenter Clinical Study of Prolonged-release Tacrolimus in Stable Pediatric Liver Transplant Recipients","status":"RECRUITING","sponsor":"RenJi Hospital","startDate":"2024-03-04","conditions":"Liver Transplant","enrollment":80},{"nctId":"NCT02921789","phase":"PHASE2","title":"Study to Assess the Efficacy and Safety of Bleselumab in Preventing the Recurrence of Focal Segmental Glomerulosclerosis in de Novo Kidney Transplant Recipients","status":"COMPLETED","sponsor":"Astellas Pharma Global Development, Inc.","startDate":"2017-05-22","conditions":"Kidney Transplantation, Primary Focal Segmental Glomerulosclerosis (FSGS)","enrollment":67},{"nctId":"NCT02118896","phase":"PHASE3","title":"Study to Ascertain if Prolonged Release Tacrolimus (FK506E - MR4) is Safe and Effective When Used in the Long Term and in Combination With Other Immunosuppressive Drugs in Patients Who Have Received a Transplant","status":"COMPLETED","sponsor":"Astellas Pharma Europe Ltd.","startDate":"2003-02-24","conditions":"Heart Transplantation, Liver Transplantation, Kidney Transplantation","enrollment":850},{"nctId":"NCT02706678","phase":"PHASE4","title":"Efficacy and Safety Study of the Switch From Cyclosporin to Tacrolimus in Renal Transplant Recipients","status":"COMPLETED","sponsor":"Astellas Pharma China, Inc.","startDate":"2010-12-29","conditions":"Renal Transplant Recipients","enrollment":105},{"nctId":"NCT01011205","phase":"PHASE3","title":"Phase 3b Study to Evaluate Advagraf in Combination With Mycophenolate Mofetil and Basiliximab in Liver Transplantation","status":"COMPLETED","sponsor":"Astellas Pharma Inc","startDate":"2009-09-30","conditions":"Liver Transplantation","enrollment":893},{"nctId":"NCT01371344","phase":"PHASE4","title":"A Paediatric, Open, Follow up Study With Modigraf Examining Safety and Efficacy in de Novo Allograft Recipients","status":"TERMINATED","sponsor":"Astellas Pharma Europe Ltd.","startDate":"2011-06-24","conditions":"Heart Transplantation, Kidney Transplantation, Liver Transplantation","enrollment":47},{"nctId":"NCT02268201","phase":"PHASE4","title":"A Study to Evaluate the Efficacy and Safety in Kidney Transplant Recipients When Changed From Cyclosporine to Tacrolimus Prolonged-release Capsule or Tacrolimus Capsule","status":"TERMINATED","sponsor":"Astellas Pharma China, Inc.","startDate":"2013-07-23","conditions":"Kidney Transplant Recipients","enrollment":17},{"nctId":"NCT02457221","phase":"PHASE3","title":"A Study to Compare the Efficacy and Safety of Tacrolimus Capsules and Cyclophosphamide Injection in Treatment of Lupus Nephritis","status":"COMPLETED","sponsor":"Astellas Pharma China, Inc.","startDate":"2015-03-10","conditions":"Lupus Nephritis","enrollment":314},{"nctId":"NCT01763580","phase":"PHASE4","title":"A Study to Evaluate the Effect of Tacrolimus and Corticosteroid Combination Therapy in Patients With Minimal Change Nephrotic Syndrome","status":"COMPLETED","sponsor":"Astellas Pharma Korea, Inc.","startDate":"2012-07-16","conditions":"MCNS, Minimal Change Nephrotic Syndrome (MCNS)","enrollment":144},{"nctId":"NCT01410747","phase":"","title":"A Study to Evaluate the Safety and Efficacy of Tacrolimus for Lupus Nephritis Under Actual Use Situations","status":"COMPLETED","sponsor":"Astellas Pharma Inc","startDate":"2007-04-10","conditions":"Lupus Nephritis","enrollment":1484},{"nctId":"NCT02159651","phase":"","title":"A Survey for Long-term Use of Prograf Capsules in Patient With Interstitial Pneumonia","status":"COMPLETED","sponsor":"Astellas Pharma Inc","startDate":"2014-04-01","conditions":"Interstitial Pneumonia Associated With Polymyositis/Dermatomyositis","enrollment":179},{"nctId":"NCT02160054","phase":"","title":"Specified Drug Use-results Survey of Graceptor in Patients With Kidney Transplantation (Switching From Cyclosporine)","status":"COMPLETED","sponsor":"Astellas Pharma Inc","startDate":"2013-11-15","conditions":"the Maintenance Phase After Kidney Transplantation","enrollment":289},{"nctId":"NCT04701528","phase":"PHASE2","title":"Anti-Viral Effects of Voclosporin in COVID-19 Positive Kidney Transplant Recipients","status":"COMPLETED","sponsor":"Leiden University Medical Center","startDate":"2020-11-15","conditions":"Covid19, Kidney Transplant Infection","enrollment":20},{"nctId":"NCT03225417","phase":"PHASE1, PHASE2","title":"Ixazomib in the Prophylaxis of Chronic Graft-versus-host Disease.","status":"ACTIVE_NOT_RECRUITING","sponsor":"Fundación Pública Andaluza para la gestión de la Investigación en Sevilla","startDate":"2017-05-16","conditions":"Hematopoietic Stem Cell Transplantation, Multiple Myeloma","enrollment":142},{"nctId":"NCT05744635","phase":"","title":"Assessment of the Pharmacokinetic Profile of Tacrolimus Medications and Their Relation to Effectiveness and Safety in Liver Transplant Patients","status":"RECRUITING","sponsor":"Chiesi Hungary Ltd.","startDate":"2023-05-10","conditions":"Liver Failure","enrollment":110},{"nctId":"NCT03511560","phase":"PHASE4","title":"Envarsus on the Effect of Total Tacrolimus Dose/Trough Level Ratio on Renal Function (eGFR) in Kidney Transplantation","status":"COMPLETED","sponsor":"Columbia University","startDate":"2018-07-26","conditions":"Renal Transplant Rejection, Kidney Transplant Failure and Rejection","enrollment":50},{"nctId":"NCT03794492","phase":"PHASE4","title":"Impact of Lymphocyte Anti-metabolite Immunosuppressions on Donor-Specific Anti-HLA Antibody and Kidney Graft Outcome","status":"COMPLETED","sponsor":"Chong Kun Dang Pharmaceutical","startDate":"2018-03-31","conditions":"Kidney Transplant","enrollment":169},{"nctId":"NCT06268769","phase":"PHASE4","title":"Tacrolimus C:D Ratio Measured in Renal Transplant Recipients Treated With Once-daily Prolonged-release Drugs","status":"RECRUITING","sponsor":"Edward Geissler","startDate":"2024-03-09","conditions":"Immunosuppression","enrollment":300},{"nctId":"NCT04078750","phase":"NA","title":"PLATO - Medication Adherence in Transplant Recipients","status":"ACTIVE_NOT_RECRUITING","sponsor":"University of British Columbia","startDate":"2019-09-10","conditions":"Kidney Disease, Chronic, Medication Adherence, Renal Disease","enrollment":99},{"nctId":"NCT04942730","phase":"PHASE2","title":"Benadamustine, Fludarabine and Busulfan Conditioning in Recipients of Haploidentical Stem Cell Transplantation (FluBuBe)","status":"COMPLETED","sponsor":"St. Petersburg State Pavlov Medical University","startDate":"2021-01-21","conditions":"Leukemia, Acute Lymphoblastic, Myeloid Leukemia, Acute, Biphenotypic Acute Leukemia","enrollment":50},{"nctId":"NCT04788641","phase":"PHASE1","title":"Study to Assess the Effect of Sodium Zirconium Cyclosilicate on the Pharmacokinetics of Tacrolimus and Cyclosporin in Healthy Subjects","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2021-03-30","conditions":"Hyperkalaemia","enrollment":62},{"nctId":"NCT04207177","phase":"PHASE4","title":"Immunosuppressive Drugs and Gut Microbiome: Pharmacokinetic- and Microbiome Diversity Effects","status":"ACTIVE_NOT_RECRUITING","sponsor":"Oslo University Hospital","startDate":"2019-10-30","conditions":"Kidney Transplant; Complications, Immune Suppression","enrollment":100},{"nctId":"NCT04420195","phase":"PHASE2","title":"Envarsus XR in Lung Transplant","status":"COMPLETED","sponsor":"NYU Langone Health","startDate":"2020-10-23","conditions":"Lung Transplant","enrollment":41},{"nctId":"NCT06147648","phase":"PHASE4","title":"Early Conversion of Prolonged-release Tacrolimus in Liver Transplantation.","status":"NOT_YET_RECRUITING","sponsor":"Beijing Tsinghua Chang Gung Hospital","startDate":"2023-12-01","conditions":"Liver Transplantation","enrollment":352},{"nctId":"NCT02837978","phase":"PHASE4","title":"The Efficacy and Safety of Tacrolimus in Refractory Rheumatoid Arthritis Patients for 6 Months and Long-term Treatment","status":"COMPLETED","sponsor":"Qiang Shu","startDate":"2015-01","conditions":"Arthritis, Rheumatoid","enrollment":150},{"nctId":"NCT03386539","phase":"PHASE3","title":"Tacrolimus/Everolimus vs. Tacrolimus/MMF in Pediatric Heart Transplant Recipients Using the MATE Score","status":"UNKNOWN","sponsor":"Boston Children's Hospital","startDate":"2018-01-29","conditions":"Pediatric Heart Transplantation, Immunosuppression, Chronic Kidney Diseases","enrollment":211},{"nctId":"NCT04048161","phase":"PHASE4","title":"Study of Tacrolimus vs Mycophenolate Mofetil in Pediatric Patients With Nephrotic Syndrome","status":"COMPLETED","sponsor":"The Children's Hospital of Zhejiang University School of Medicine","startDate":"2019-11-12","conditions":"Nephrotic Syndrome in Children","enrollment":270},{"nctId":"NCT04725682","phase":"PHASE1","title":"Bioequivalence Study of Tacrolimus in Healthy Volunteers","status":"COMPLETED","sponsor":"Food and Drug Administration (FDA)","startDate":"2021-01-05","conditions":"Healthy Volunteers","enrollment":67},{"nctId":"NCT02341274","phase":"PHASE1","title":"Effects of Altered Formulation on the Bioequivalence of Tacrolimus in Healthy Female and Male Volunteeers","status":"COMPLETED","sponsor":"Indiana University","startDate":"2016-11-11","conditions":"Bioequivalence","enrollment":24},{"nctId":"NCT05202145","phase":"PHASE1","title":"Drug-Drug Interaction (DDI) Study of ALXN2050 in Healthy Adult Participants","status":"COMPLETED","sponsor":"Alexion Pharmaceuticals, Inc.","startDate":"2022-01-11","conditions":"Healthy","enrollment":61},{"nctId":"NCT05739630","phase":"PHASE2, PHASE3","title":"M-PTCy vs BuCy in Haploidentical HSCT for Acute Leukemia","status":"UNKNOWN","sponsor":"The First Affiliated Hospital of Soochow University","startDate":"2023-01-01","conditions":"Acute Leukemia","enrollment":60},{"nctId":"NCT04444843","phase":"PHASE4","title":"Risk Factors of Chinese Kidney Transplant Recipients DSA Based on MPA Immunosuppressive Regimen","status":"UNKNOWN","sponsor":"First Affiliated Hospital Xi'an Jiaotong University","startDate":"2021-01-22","conditions":"Kidney Transplant Recipients","enrollment":300},{"nctId":"NCT05353010","phase":"PHASE1","title":"A Study to Evaluate Effect of IN-A001 on Pharmacokinetics of Tacrolimus in Healthy Volunteers","status":"UNKNOWN","sponsor":"HK inno.N Corporation","startDate":"2022-05-01","conditions":"Healthy","enrollment":12},{"nctId":"NCT03099122","phase":"PHASE4","title":"A Study of Thymoglobuline® Induction Therapy in Adult Recipients of Donated After Cardiac Death Kidney Transplant","status":"COMPLETED","sponsor":"Sanofi","startDate":"2017-08-16","conditions":"End-stage Renal Disease","enrollment":115},{"nctId":"NCT03194321","phase":"PHASE4","title":"Trial to Evaluate Safety and Tolerability of Tacrolimus Extended-Release (Astagraf XL) in Human Leukocyte Antigen (HLA) Sensitized Kidney Transplant Recipients","status":"COMPLETED","sponsor":"Cedars-Sinai Medical Center","startDate":"2017-09-11","conditions":"End Stage Renal Disease","enrollment":20},{"nctId":"NCT05109390","phase":"PHASE1","title":"A Study of the Drug Interactions Between Danicopan and Cyclosporine, Tacrolimus, Antacids, and Omeprazole in Healthy Adults","status":"COMPLETED","sponsor":"Alexion Pharmaceuticals, Inc.","startDate":"2018-07-27","conditions":"Healthy","enrollment":72},{"nctId":"NCT02588339","phase":"PHASE2","title":"Panobinostat (LBH589): Acute Graft Versus Host Disease (aGVHD) Prevention","status":"COMPLETED","sponsor":"H. Lee Moffitt Cancer Center and Research Institute","startDate":"2016-03-04","conditions":"Graft Versus Host Disease, GVHD","enrollment":42},{"nctId":"NCT02540395","phase":"NA","title":"Prospective Donor Specific T Response Measurment for IS Minimization in de Novo Renal Transplantation","status":"COMPLETED","sponsor":"Prof. Dr. Petra Reinke","startDate":"2015-03","conditions":"Disorder Related to Renal Transplantation, Effects of Immunosuppressant Therapy","enrollment":184},{"nctId":"NCT03749356","phase":"PHASE4","title":"Study to Evaluate the Efficacy and Safety of Once-Daily Tacrolimus in Kidney Transplant Recipients","status":"COMPLETED","sponsor":"Chong Kun Dang Pharmaceutical","startDate":"2018-09-05","conditions":"Kidney Transplant","enrollment":141},{"nctId":"NCT04633733","phase":"PHASE1","title":"The Study of Pharmacokinetic Interactions Between HL237 and Tacrolimus","status":"UNKNOWN","sponsor":"Hanlim Pharm. Co., Ltd.","startDate":"2020-08-22","conditions":"Healthy Male Volunteers","enrollment":24},{"nctId":"NCT00914940","phase":"PHASE2","title":"Selective Depletion of CD45RA+T Cells From Allogeneic Peripheral Blood Stem Cell Grafts for the Prevention of GVHD","status":"TERMINATED","sponsor":"Fred Hutchinson Cancer Center","startDate":"2009-12-17","conditions":"Graft Versus Host Disease, Leukemia, Myelodysplastic Syndromes","enrollment":41},{"nctId":"NCT02500212","phase":"PHASE4","title":"Pharmacokinetic Study of ENVARSUS in Adult De-novo Kidney Transplant Patients","status":"COMPLETED","sponsor":"Chiesi Farmaceutici S.p.A.","startDate":"2015-07","conditions":"Organ or Tissue Transplant; Complications","enrollment":75},{"nctId":"NCT03216447","phase":"PHASE4","title":"A Study of Patient Adherence and Convenience to Immunosuppressive Agents in Newly Liver Transplant","status":"UNKNOWN","sponsor":"Chang Gung Memorial Hospital","startDate":"2017-11-23","conditions":"Liver Transplantation","enrollment":150},{"nctId":"NCT03828682","phase":"PHASE4","title":"Veloxis de Novo Kidney Transplant ECSWD","status":"UNKNOWN","sponsor":"Simon Tremblay, PharmD, PhD","startDate":"2019-06-21","conditions":"Kidney Transplantation, Immunosuppression","enrollment":60},{"nctId":"NCT04292418","phase":"","title":"Predictors of Rejection in Pediatric Kidney Transplantation","status":"UNKNOWN","sponsor":"Assiut University","startDate":"2020-05-01","conditions":"Rejection Acute Renal","enrollment":70},{"nctId":"NCT04224350","phase":"PHASE4","title":"Study to Evaluate the Efficacy and Safety of Tacrolimus in Kidney Transplant Recipients (BLOSSOM)","status":"UNKNOWN","sponsor":"Chong Kun Dang Pharmaceutical","startDate":"2018-12-17","conditions":"Kidney Transplant","enrollment":184},{"nctId":"NCT04102943","phase":"PHASE4","title":"Study to Evaluate the Pharmacokinetics and Tolerability of Tacrolimus in Kidney Transplant Recipients.","status":"UNKNOWN","sponsor":"Chong Kun Dang Pharmaceutical","startDate":"2017-11-30","conditions":"Kidney Transplant","enrollment":128},{"nctId":"NCT02953873","phase":"PHASE4","title":"Dosing Requirements of Astagraf XL® in African American Kidney Transplant Recipients","status":"COMPLETED","sponsor":"Medical University of South Carolina","startDate":"2017-05-05","conditions":"Immunosuppression","enrollment":25},{"nctId":"NCT03918265","phase":"PHASE4","title":"Tacrolimus Treatment for Refractory Autoimmune Cytopenia","status":"UNKNOWN","sponsor":"Peking Union Medical College Hospital","startDate":"2019-05-04","conditions":"Autoimmune Hemolytic Anemia, Pure Red Cell Aplasia, Evans Syndrome","enrollment":80},{"nctId":"NCT01536535","phase":"PHASE4","title":"Predicting Response to Standardized Pediatric Colitis Therapy","status":"COMPLETED","sponsor":"Connecticut Children's Medical Center","startDate":"2012-07-10","conditions":"Ulcerative Colitis","enrollment":431},{"nctId":"NCT03978494","phase":"PHASE1","title":"Study to Compare Pharmacokinetics of Tacrolimus Prolonged-release (PR) Capsules and Advagraf® PR Capsules in Stable Kidney Transplant Patients.","status":"WITHDRAWN","sponsor":"Sandoz","startDate":"2019-09-02","conditions":"Kidney Transplant","enrollment":""},{"nctId":"NCT01649427","phase":"PHASE4","title":"Comparison of a Tacrolimus Hexal® Based Regimen Versus a Prograf® Based Regimen in de Novo Renal Transplant Recipients","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2012-10-17","conditions":"Pharmacokinetics Study in de Novo Kidney Transplantation","enrollment":73},{"nctId":"NCT00629122","phase":"PHASE4","title":"Pharmacokinetics of Sublingual Versus Oral Tacrolimus in Patients Awaiting Kidney Transplantation","status":"COMPLETED","sponsor":"Weill Medical College of Cornell University","startDate":"2008-02","conditions":"Kidney Failure, Chronic","enrollment":5},{"nctId":"NCT01551212","phase":"PHASE4","title":"Efficacy of Everolimus in Combination With Tacrolimus in Liver Transplant Recipients","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2012-05-24","conditions":"Liver Transplantation","enrollment":339},{"nctId":"NCT03549663","phase":"NA","title":"Tacrolimus Monotherapy for Idiopathic Membranous Nephropathy (IMN)","status":"UNKNOWN","sponsor":"Xinhua Hospital, Shanghai Jiao Tong University School of Medicine","startDate":"2018-07-04","conditions":"Idiopathic Membranous Nephropathy","enrollment":108},{"nctId":"NCT02115113","phase":"PHASE3","title":"REnal Function in Liver Transplantation: Everolimus With Calcineurin Inhibitor (CNI)-Sparing sTrategy","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2014-03-28","conditions":"Liver Transplantation","enrollment":78},{"nctId":"NCT01938625","phase":"PHASE2","title":"A Study of Pharmacokinetics, Efficacy, Safety, Tolerability, of the Combination of Simeprevir (TMC435), Daclatasvir (BMS-790052), and Ribavirin (RBV) in Patients With Recurrent Chronic Hepatitis C Genotype 1b Infection After Orthotopic Liver Transplantation","status":"COMPLETED","sponsor":"Janssen R&D Ireland","startDate":"2013-12-12","conditions":"Hepatitis C, Chronic","enrollment":35},{"nctId":"NCT00862979","phase":"PHASE4","title":"A Study Investigating the Renal Tolerability, Efficacy, and Safety of a CNI-free Versus a Standard Regimen in de Novo Heart Transplant (HTx) Recipients","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2009-02-24","conditions":"Heart Transplantation","enrollment":162},{"nctId":"NCT01962922","phase":"PHASE3","title":"Crossover Study to Compare PK of Once Daily LCP-Tacro Tablets to Generic Tacrolimus Capsules Twice Daily.","status":"COMPLETED","sponsor":"Veloxis Pharmaceuticals","startDate":"2013-11","conditions":"Renal Failure","enrollment":50},{"nctId":"NCT03540472","phase":"PHASE4","title":"Tacrolimus Treatment for Refractory PRCA","status":"UNKNOWN","sponsor":"Peking Union Medical College Hospital","startDate":"2018-06-10","conditions":"Pure Red Cell Aplasia","enrollment":30},{"nctId":"NCT02432833","phase":"PHASE4","title":"Multicentre, Open Label, Randomized, Two-arm, Parallel-group Study to Assess Efficacy and Safety of ENVARSUS® Compared With Tacrolimus Used as Per Current Clinical Practice in the Initial Maintenance Setting in de Novo Kidney Transplant Patients","status":"COMPLETED","sponsor":"Chiesi Farmaceutici S.p.A.","startDate":"2015-05","conditions":"End Stage Renal Disease","enrollment":428},{"nctId":"NCT02373202","phase":"PHASE3","title":"A Study Assessing the Safety and Efficacy of Sarilumab Added to Non-MTX DMARDs or as Monotherapy in Japanese Patients With Active Rheumatoid Arthritis (SARIL-RA-HARUKA)","status":"COMPLETED","sponsor":"Sanofi","startDate":"2015-02","conditions":"Rheumatoid Arthritis","enrollment":91},{"nctId":"NCT02336854","phase":"PHASE1","title":"Tacrobell tab_Phase1_PK","status":"COMPLETED","sponsor":"Chong Kun Dang Pharmaceutical","startDate":"2015-01-12","conditions":"Immunosuppressant(Organ Transplantation, RA)","enrollment":50},{"nctId":"NCT01843348","phase":"PHASE3","title":"12 Month Athena Study: Everolimus vs. Standard Regimen in de Novo Kidney Transplant Patients","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2012-12-27","conditions":"Kidney Transplantation, Renal Transplantation","enrollment":612},{"nctId":"NCT01353417","phase":"","title":"Non-interventional-study With Tacrolimus Sandoz© Capsules for Prophylaxis of Renal Graft Rejection","status":"COMPLETED","sponsor":"Sandoz","startDate":"2011-04","conditions":"Chronic Kidney Insufficiency","enrollment":102},{"nctId":"NCT03062813","phase":"PHASE4","title":"Tacrolimus Combined With Entecavir on HBV Associated Glomerulonephritis(HBV-GN)","status":"UNKNOWN","sponsor":"Guangdong Provincial People's Hospital","startDate":"2017-02-01","conditions":"Hepatitis B Virus Associated Nephrotic Syndrome","enrollment":112},{"nctId":"NCT00087581","phase":"PHASE4","title":"Study of Therapeutic Monitoring of Mycophenolate Mofetil (MMF/CellCept) After Kidney Transplantation","status":"COMPLETED","sponsor":"Hoffmann-La Roche","startDate":"2004-06","conditions":"Kidney Transplantation","enrollment":720},{"nctId":"NCT01187953","phase":"PHASE3","title":"Double-Blind,Double-Dummy,Efficacy/Safety,LCP-Tacro™ Vs Prograf®,Prevention Rejection,De Novo Adult Kidney Tx","status":"COMPLETED","sponsor":"Veloxis Pharmaceuticals","startDate":"2010-09","conditions":"Renal Failure","enrollment":543},{"nctId":"NCT01325571","phase":"PHASE3","title":"A Study to Compare the Efficacy and Safety of Tacrolimus Capsules in Patient With Myasthenia Gravis","status":"COMPLETED","sponsor":"Astellas Pharma Inc","startDate":"2011-03","conditions":"Myasthenia Gravis","enrollment":83},{"nctId":"NCT02660684","phase":"PHASE4","title":"Study to Assess the Safety and Efficacy of Tacrolimus (Prograf Capsule/Injection) and Methotrexate (MTX) Combination Therapy for Prevention of Graft Versus Host Disease (GVHD) in Patients Who Received Peripheral Hematopoietic Stem Cell Transplantation From a Sibling Donor","status":"COMPLETED","sponsor":"Astellas Pharma Korea, Inc.","startDate":"2008-02","conditions":"Graft Versus Host Disease","enrollment":39},{"nctId":"NCT00619398","phase":"PHASE3","title":"A Study to Evaluate and Compare the Efficacy and Safety of FK506MR vs Prograf® in Stable Liver Transplantation Patients","status":"COMPLETED","sponsor":"Astellas Pharma Inc","startDate":"2008-01","conditions":"Liver Transplantation","enrollment":172},{"nctId":"NCT01889758","phase":"PHASE4","title":"Pharmacokinetic Studies of Tacrolimus in Transplant Patients","status":"COMPLETED","sponsor":"University of Cincinnati","startDate":"2013-06","conditions":"Kidney Transplant Recipients, Liver Transplant Recipients","enrollment":78},{"nctId":"NCT02339246","phase":"PHASE3","title":"Pharmacokinetic Comparison Of All FK-506 Formulations","status":"COMPLETED","sponsor":"Veloxis Pharmaceuticals","startDate":"2015-01","conditions":"Renal Failure","enrollment":32},{"nctId":"NCT01744067","phase":"PHASE4","title":"The Effects of Omega-3 Fatty Acids in Renal Transplantation","status":"COMPLETED","sponsor":"Oslo University Hospital","startDate":"2013-11","conditions":"Disorder Related to Renal Transplantation","enrollment":132},{"nctId":"NCT01025817","phase":"PHASE3","title":"Non-inferiority Study of Safety and Efficacy of Everolimus With Low Dose Tacrolimus to Mycophenolate Mofetil With Standard Dose Tacrolimus in Kidney Transplant Recipients","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2010-01","conditions":"Kidney Transplant","enrollment":613},{"nctId":"NCT01870908","phase":"","title":"Special Drug Use-Results Survey of Prograf Capsule in Rheumatoid Arthritis Patients","status":"COMPLETED","sponsor":"Astellas Pharma Inc","startDate":"2012-08","conditions":"Rheumatoid Arthritis","enrollment":664},{"nctId":"NCT01438710","phase":"PHASE3","title":"Switching Study of Kidney Transplant Patients With Tremor to LCP-Tacro (STRATO)","status":"COMPLETED","sponsor":"Veloxis Pharmaceuticals","startDate":"2011-12","conditions":"Renal Failure, Tremors","enrollment":44},{"nctId":"NCT00817206","phase":"PHASE3","title":"Safety and Efficacy of LCP-Tacro™ Once Daily in Stable Renal Transplant Patients Converted From Prograf® Twice Daily","status":"COMPLETED","sponsor":"Veloxis Pharmaceuticals","startDate":"2008-12","conditions":"Renal Failure","enrollment":326},{"nctId":"NCT01410162","phase":"PHASE4","title":"Advagraf/Prograf Conversion Trial","status":"COMPLETED","sponsor":"Norman Muirhead","startDate":"2010-12","conditions":"Renal Transplant, Kidney Pancreas Transplant","enrollment":53},{"nctId":"NCT00608244","phase":"PHASE2","title":"Pharmacokinetics of LCP-Tacro in Stable Liver Transplant Patients","status":"COMPLETED","sponsor":"Veloxis Pharmaceuticals","startDate":"2007-11","conditions":"Liver Failure","enrollment":59},{"nctId":"NCT01842269","phase":"PHASE4","title":"Evaluate the Efficacy and Safety of My-Rept® Tablet vs. My-Rept® Capsule in Combination With Tacrolimus in Kidney Transplant Patients","status":"COMPLETED","sponsor":"Chong Kun Dang Pharmaceutical","startDate":"2013-01","conditions":"Kidney Transplantation","enrollment":156},{"nctId":"NCT00496483","phase":"PHASE2","title":"Pharmacokinetics of LCP-Tacro in Stable Kidney Transplant Patients","status":"COMPLETED","sponsor":"Veloxis Pharmaceuticals","startDate":"2007-07","conditions":"Renal Failure","enrollment":60}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":9,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Tac-arm","Envarsus®XR.","tacrobell tablet","Protopic®","Advagraf"],"phase":"marketed","status":"active","brandName":"Tacrolimus capsule","genericName":"Tacrolimus capsule","companyName":"Oslo University Hospital","companyId":"oslo-university-hospital","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Tacrolimus inhibits calcineurin phosphatase, blocking T-cell activation and proliferation by preventing transcription of IL-2 and other cytokine genes. Used for Organ transplant rejection prophylaxis (kidney, heart, liver, pancreas), Atopic dermatitis, Autoimmune conditions (off-label use in various settings).","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":1,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}